Temporally Programmed CD8?+ DC Activation Enhances Combination Cancer Immunotherapy.

ABSTRACT: Numerous synergistic cancer immunotherapy combinations have been identified, but the effects of relative dose timing are rarely considered. In established syngeneic mouse tumor models, we found that staggering interferon-? (IFN?) administration after, rather than before or simultaneously with, serum-persistent interleukin-2 (IL-2) and tumor-specific antibody significantly increased long-term survival. Successful combination therapy required IFN?-induced activation of cross-presenting CD8?+ dendritic cells (DCs) following the release of antigenic tumor debris by the IL-2- and antibody-mediated immune response. Due to decreased phagocytic ability post-maturation, DCs activated too early captured less antigen and could not effectively prime CD8+ T cells. Temporally programming DC activation to occur after tumoricidal activity enhanced tumor control by multiple distinct combination immunotherapies, highlighting dose schedule as an underappreciated factor that can profoundly affect the success of multi-component immunotherapies.

SUBMITTER: Tzeng A 

PROVIDER: S-EPMC5204262 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature